Background: Leishmaniasis is a worldwide disease prevalent in tropical and sub- tropical coun-tries. In the present study the immunogenicity of three human HLA-DR1 restricted peptides de-rived from L. major gp63 protein was evaluated using FVB/N-DR1 transgenic mouse model. Methods: The immunity generated by three MHC class II – restricted peptides with the sequence of AARLVRLAAAGAAVT (AAR), AAPLVRLAAAGAAVT (AAP) and ASRYDQLVTRVVTHE (ASR) derived from L. major gp63 protein were predicted using a web-based software (SYFPEITHI) and tested in FVB/N-DR1 transgenic mice. Results: Immunisation of FVB/N-DR1 transgenic mice with one of the three predicted peptides (AAR) resulted in high levels of Th1-type immune response as well as significant levels of IFN-γ de tected by Proliferation assay and ELISA. Conclusion: The results indicate a high level of immunogenicity for AAR, which can be a potent candidate for peptide vaccine in Leishmania infections.
